

**COMPANY REGISTRATION NUMBER 02939840**



**THE  
NEUROLOGICAL  
ALLIANCE**

**THE NEUROLOGICAL ALLIANCE**

**(LIMITED BY GUARANTEE)**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED**

**30 JUNE 2023**

**Charity Number 103903**

**THE NEUROLOGICAL ALLIANCE**  
**TRUSTEE ANNUAL REPORT**  
**LETTER FROM THE CHAIR**

This annual report bears witness to the big strides we have taken that have shaped our path this past year.

Against the backdrop of a world that continues to grapple with uncertainties, the spirit and resilience of our community has shone brighter than ever. At the core of this lies a fundamental shift – the increased involvement of people affected by neurological conditions in our endeavours. This transformation has enriched our work and made us more effective and influential in advocating for the change our community deserves.

We now have more than 100 members. Over a dozen organisations joined us in 2022-23. This is the biggest increase in membership in our near 30-year history and stands as a testament to the resonance of our mission and the trust placed in us by individuals and organisations alike.

The increase in the number of people on NHS waiting lists in England, continued pressures on our health and care workforce and increases in the cost of living serve as a stark reminder of the urgency of our mission. The commitment we make today is not merely to challenge numbers or statistics, but to highlight the lives that lie behind them. It is a commitment to transform pathways of access, to seek out and highlight timely interventions, and to replace uncertainty with hope.

More than 100 organisations and 19,000 people have come together this year to call for urgent action to support the 1 in 6 across the country who live with a neurological condition. Despite a hugely challenging external environment, we have generated much needed momentum for positive change. As a general election looms, we must capitalise on this and ensure the neurological community is heard by candidates and political parties alike.

Our compass remains guided by the principle that each individual's journey is unique and deserving of dignity and support. Through collaboration with like-minded organisations, we are determined to increase our impact and to ensure that the voices of those affected by neurological conditions resonate far and wide.

This annual report is a snapshot of our collective efforts. As you delve into its pages, I invite you not only to see the numbers and achievements but to feel the pulse of a community bound by compassion, united by purpose, and driven by the shared vision of a brighter, more inclusive future.

**David Martin, Chair, The Neurological Alliance**

**THE NEUROLOGICAL ALLIANCE  
ANNUAL REPORT AND ACCOUNTS  
YEAR ENDED JUNE 2023**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered charity name**                      The Neurological Alliance

**Charity registration number**                1039034

**Company registration number**              02939840

**Registered office**                              The Junction  
Station Road  
Watford  
Hertfordshire  
WD17 1EU  
Watford

**Independent Examiner**                      Martin Bailey FCA  
Goodman Jones LLP  
Chartered Accountants  
29-30 Fitzroy Square  
London  
W1T 6LQ

**Accountants**                                    Godfrey Wilson  
5th Floor, Mariner House  
62 Prince Street  
Bristol  
BS1 4QD

**Bankers**

CAF Bank Ltd

25 Kings Hill Avenue

Kings Hill

West Malling

Kent

ME19 4JQ

Metro Bank PLC

One Southampton Row

London

WC1B 5HA

The trustees present their report and independently examined financial statements for The Neurological Alliance for the year 1 July 2022 to 30 June 2023. The report and financial statements have been prepared in accordance with the Companies Act 2006 and the Charities Act 2011. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) effective January 2019 in preparing the report and financial statements. The report and financial statements will be laid before the members of the charity at the Annual General Meeting to be held on 22 November 2023. In preparation of this report, the trustees had regard for the Charity Commission guidance on public benefit.

## **1. Our objects**

Our principal objectives, as derived from the objects set out in our Articles of Association, are to advance the education of the public in all matters concerning neurological disorders by carrying out research and investigation into preventative procedures, treatment and the needs and care of persons affected by neurological conditions, and publishing the useful results thereof, and the relief of those persons in the United Kingdom of Great Britain and Northern Ireland who are receiving or have received treatment for neurological conditions.

We are the only collective voice for over 100 national charities, professional bodies, regional organisations and corporate organisations working together to transform treatment, care and support for people affected by neurological conditions.

## **2. What we set out to do in 2022-23**

Our mission is to raise awareness and understanding of neurological conditions to ensure that every person diagnosed with a neurological condition has access to high quality, joined up services and information from their first symptoms, throughout their life.

We conducted a thorough review of our organisational strategy in 2022. Our new strategy, "Together for the 1 in 6: Our strategy to deliver change 2022 - 2027" was developed using insight from people affected by neurological conditions, our membership and the wider external environment. It was clear that our direction of travel was broadly correct. However, we needed to be more bold in our ambition, and deepen the involvement of people affected by neurological conditions throughout our work.

Our revised vision, mission and strategic goals are as follows:

- Vision: Every person affected by a neurological condition can access the right treatment, care and support at the right time.
- Mission: To harness the energy and passion of the neurological community to ensure public policy in health reflects the realities of living with a neurological condition, so that everyone can access treatment, care and support whenever they need it.

Our goals:

1. Public policy and practice reflects and supports the realities of living with a neurological condition
2. People affected by neurological conditions and our members are heard and have influence
3. We are a strong, diverse organisation that delivers change

Our values:

- **Bold:** We will not hesitate to speak truth to power, rooted in the experiences of people with neurological conditions.
- **United:** We unleash the power of our collective community.
- **Inclusive:** We listen to and celebrate the diversity of the neurological community. We work with anyone who shares our vision.
- **Leading:** We are the voice on issues relating to access and experience of healthcare for people with neurological conditions.
- **Expert:** We deliver evidence that changes minds and policy.

The Annual Report of the Trustees for 2022/23 is set out under our three strategic goals:

### **Goal 1: Public policy and practice reflects and supports the realities of living with a neurological condition**

In an incredibly changeable and challenging external environment, we have managed to secure much needed momentum to improve services for people affected by neurological conditions.

We successfully co-ordinated a [joint letter](#) to the Secretary of State for Health and Social Care, Steve Barclay, supported by 44 member organisations, calling for the inclusion of neurological conditions in the scope of the proposed Major Conditions Strategy. Influencing activities around the strategy continued with a [news piece](#) on the announcement of the call for evidence, and our [response](#). We also met with the Major Conditions Strategy team from the Department of Health and Social Care, sharing a briefing paper and securing engagement events with members and people affected by neurological conditions. These are going ahead in Autumn 2023.

We responded to the call for evidence for the Hewitt Review and separately, the Health and Social Care Committee inquiry on Integrated Care Systems. Our Chief Executive was invited to join the Hewitt Review workstreams into data and digital. Upon publication of the two reports, we summarised our responses, report outcomes and next steps in an online news story.

We have worked with NHS England to help steer the neuroscience transformation review. The review recognises two areas of neuroscience (neurology and neurosurgery) as two specialties in need of improvement, particularly given the forthcoming delegation of specialised commissioning responsibilities to a local level. The transformation programme will set out a new model of commissioning (within and between Integrated Care Systems and the national NHS England specialised commissioning team), with a view to providing improved, co-ordinated care. The National Clinical Directors for neurosurgery and spinal surgery, and neurology, are leading the review. Our Chief Executive is a member of the NHS England Neuroscience Transformation Programme Board.

In parallel, we have continued to hold a national role on the NHS England Clinical Reference Group (CRG) for neurology. The group advises NHS England on clinical policy, commissioning policy and guidance and service specification development. As a member of this group, we have supported greater involvement of people affected by neurological

conditions within discussions and sought to ensure public policy reflects the realities of living with a neurological condition.

The Acquired Brain Injury (ABI) Strategy, which was successfully secured by charities and individuals from across the brain injury community, represents an important opportunity for change. The strategy applies across the UK, and we have played an active role in the Public and Patient Voice Group for the Strategy. The Strategy is likely to be published in 2024.

We continued to work closely with clinicians and members to develop optimal pathways for a range of neurological conditions. Five pathways (on functional neurological disorders, movement disorders, headache and facial pain, motor neurone disease and traumatic brain injury) have now been published and shared across the neurological community. They set out what good care should look and feel like and have been endorsed by a range of organisations. Our huge thanks to every clinician, person affected by a neurological condition and organisation, who has taken the time to provide input into the pathways and share them with their networks.

We also developed a new 'Service Improvement Navigator' tool for epilepsy. The tool, which was developed following interviews with people affected by epilepsy, Regional Neurological Alliances and clinicians, includes a range of resources to support service development. The tool has been warmly received by commissioners and providers, and we intend to develop new tools for a range of conditions in the future. Our thanks to UCB for sponsoring this project.

Finally, we have been working with our Mental Health Group and mental health specialists to develop research into the contractual barriers to mental health support for people affected by neurological conditions. This work will form an important basis of the Mental Health Group's agenda in 23/24.

## **Goal 2: People affected by neurological conditions and our members are heard and have influence**

The #BackThe1in6 campaign, calling for a UK-wide Neuro Taskforce, was supported by over 100 organisations and more than 19,000 people through our e-petition. It is our largest public facing campaign to date. The petition was handed into the Department of Health and Social Care on 5 June 2023 together with members of our Co-production Group. Its receipt was confirmed by the Minister of State, Helen Whately MP, in response to a [written Parliamentary Question](#).

To coincide with the petition hand-in, we organised a parliamentary drop-in event to engage with MPs on the campaign and calls for a UK Neuro Taskforce. A campaigner e-action was developed, leading to over 1,400 people inviting their MP to attend the drop-in. 22 MPs were represented at the event including members from all main political parties – the highest number of MPs to attend a Neurological Alliance event to date.

The #BackThe1in6 campaign has been shaped and steered by The Neurological Alliance co-production group. Members of the group live with one or more neurological conditions and live in different parts of the UK. The group brings together people of different ages, backgrounds and ethnicities. All have personal experiences of the daily challenges of living with different neurological conditions. Members of the group have been meeting weekly online since its inception in March 2022, and all are passionate about ensuring that the governments of all four nations in the UK commit to forming a Neuro Taskforce to create a seamless, appropriate and adequate health and care service, for life, for the millions of people living with a neurological condition in the UK and their families.

The group have used their expertise and insight to create campaign messages and blogs, decide the look and feel of the hand-in and drop-in events, and work together to design a collective video artwork that was displayed in Parliament and T-shirts containing unique personal messages highlighting the need for a UK-wide Neuro Taskforce. The group have kindly pulled together a note on their experiences this past year, which is below.

### **A note from the Co-production Group**

Being involved in the Co-production Group has opened different doors.

It's been an opportunity to engage with some of the member organisations from the Alliance, it's opened doors in places I wouldn't have had the opportunity to go if I hadn't been involved in the Co-production Group. It's led to other opportunities around different aspects of my condition and the brain tumour.

We all became involved in the Co-production group in different ways – some of us can't remember how! Rhys and Jeanie became involved after completing My Neuro Survey and ticking the box that said we were happy to stay in contact. Jeanette was recruited through the Northern Ireland Neurological Charities Alliance. Rebecca came to the group through Alliance member charity, the MS Society, and Trishna saw an advert on The Neurological Alliance website. As part of the Co-production Group, we've all been involved in shaping the Back the 1 in 6 campaign and related activities, including the petition hand-in and campaign materials.

We all have varying levels of experience of co-production too. Debbie says she jumped at the chance to make a valuable contribution to the whole neurological community, as well as for acquired brain injury survivors like her. Some of us are quite surprised to still be involved 18 months later! We thought it would be a week or two project, which would be a bit of consultation on our opinion and then the Alliance would go away and do its own thing.

But this is what we like about the Co-production Group: it's a proactive group. It's not lipservice. It's not a tick box exercise. Often, people are just looking to tick the box that says "we must speak to people with lived experience" rather than actively engaging with them.

This is not the case with our Co-production Group – we've become part of the group and we've been able to influence the work of the Alliance, particularly the #BackThe1in6 campaign. That's been the big benefit. Co-production has meant co-production.

It was exciting to work together because it was a new way of working. We got to work together with other people with personal experience of a range of different neurological conditions. We learned new things. It's rewarding because the whole co-production group shared knowledge, ideas, tips and experience. We were flying high and combining the hard work and enthusiasm of people from across the UK. We are all quietly enthusiastic.

Putting this together we were all asked to pick one thing that was best about working in the co-production group and that's really hard because it's given us each a range of new experiences. We've enjoyed the friendships that have developed, even though we are sometimes hundreds of miles apart. You get to know each other and it's nice to see each other on Zoom.

The Co-production Group has highlighted how important it is to speak to people living with neurological conditions. It can't just be doctors and politicians trying to do their jobs: you need to have people with neurological conditions involved shaping campaigns, services and healthcare that is meant for them. It's been really beneficial to have conversations with other people with neurological conditions, even though our neurological conditions are different and are symptoms might be different there is a commonality with all of us, and we've learned about what different things might affect different parts of the neurological community and



established common ground between us. We all seem to have a struggle one way or another with health services. And often it's because they think they know what we want but often they've never asked, and they've not communicated. It's not patient-centred and this needs to change.

The Co-production Group has been really useful in helping us realise that you are not battling alone as a person with a neurological condition. You can be very isolated and on your own and because of that you think you're making a big deal of something, and perhaps you are the only one with the problem and perhaps you're being a bit over-the-top or paranoid, but in actual fact what working in the Co-production Group has shown is that we've all got a valid claim to have good, holistic and cohesive support.

We married everything together and came together as one voice. We all have different conditions, but as the Co-production Group, we were able to come together as one and say, "We all need this". We are being listened to. Co-production makes you feel more comfortable about talking about your experiences and sharing. So, then you get a little more clarity on how to explain it to others when you need to and how to say, "this is how I feel, this is what I need" and getting other people to listen to those things. Co-production has been about driving things in the direction you want to see them go in – for yourself and others, and the care they need – and having some change happen.

Over a dozen parliamentary questions discussing neurological conditions have been tabled since the #Backthe1in6 petition was handed in and further support has been garnered for a pan-neuro debate application.

Working with an external PR agency, we secured 26 pieces of media coverage for the campaign to coincide with the petition hand-in – 17 online articles, 8 print and 1 radio item. Coverage included BBC regional radio and leading regional titles including The Yorkshire Post and Express and Star.

The #BackThe1in6 petition link has been shared hundreds of times by member organisations, reaching thousands of people across Facebook, Twitter (X), LinkedIn, and Instagram. Over 300 people sent in their pictures to be part of the collective mosaic artwork that was displayed in Parliament on 5 June, which has been viewed over 5,000 times to date on Twitter (X) alone.

We delivered a varied and engaging series of member meetings this year. Policy Group highlights included a panel discussion on the needs of the neuroscience workforce with professional bodies and a session unpacking what NHS reform in England means for neuroscience services and those who use them.

We were delighted to welcome Charlotte Gerada, Policy and Public Affairs Manager at the Huntington's Disease Association as our incoming Policy Group Chair. Our thanks go to our former co-chairs Sam Freeman-Carney and Dawn Golder for their leadership and support of the group during their terms.

The Rare Conditions group continued to meet, discussing the England Rare Conditions Action Plan with colleagues from the Department of Health and Social Care and hearing from Rare Minds about mental health support for people affected by rare neurological conditions. Mental Health Group highlights included developing our response to the Government's 10-year Mental Health and Wellbeing Plan Consultation. We also welcomed Prof. Hugh Rickards, Neuropsychiatrist, to the group to discuss common barriers to mental health support for people affected by neurological conditions. More broadly, the Group have continued to engage with our joint research project on identifying contractual or commissioning barriers to accessing mental health services.

The Alliance hosted quarterly meetings for CEOs and Chairs of Regional Neurological Alliances to join together for peer support and to discuss their challenges and successes and to share experiences. Thanks to Kripen Dhrona, Alliance trustee and CEO of the British Polio Fellowship for chairing these meetings. Members of the group valued the peer support and in the evaluation. At the June 2023 meeting CEOs heard from the National Clinical Director for Neurology, Dr Niran Nirmalanathan, who reflected on six months in the role. He stressed that collaboration across condition areas was vital to avoid the fragmentation of our voices.

We have continued to work closely with the Brain and Spine Foundation to deliver NeuroLifeNow, a real-time survey which aims to provide routine patient experience data to support service improvement and positive public policy change. To date, more than 4,000 people have shared their experiences through the platform. We worked with the Brain and Spine Foundation to give new resources to our membership to promote the platform, including a webinar attended by a range of organisations, held in March 2023. Together, the NeuroLifeNow team published seven new reports in 2022-2023.

Finally, experiences shared through My Neuro Survey continue to have a significant impact. We have shared the data at no less than a dozen professional conferences and continue to receive requests for Integrated Care System level data from commissioners and providers alike. Our thoughts are now turning to the next iteration of the survey, which will be conducted in 2024.

### **Goal 3: We are a strong, diverse organisation that delivers change**

We are nothing without our members, and 2022/23 was a year of significant growth. More than 100 members from across the neurological community are now part of the Alliance network.

From July 2022-June 2023 the Board approved 17 applications for membership. Members who have joined the Alliance include Alex-The Leukodystrophy Charity, Behcets UK, the Brain Charity, CSF Leak, FND Dimensions, Hereditary Brain Aneurysms Support (HBA Support), Intractable Epilepsy, Pans Pandas UK, Shift MS, the Timothy Syndrome Alliance (TSA), and 3 Million Steps. We were pleased to welcome back the Pernicious Anaemia Society and to agree reciprocal arrangements with the Genetic Alliance and the Northern Ireland Neurological Charities Alliance (niNCA).

Our annual membership survey provides the chance for members to comment formally on the strengths of the Alliance and to give us critical comments on what can be improved. In 2023 97% of respondents said the Alliance represents good or excellent value for money. 93% agree we are a strong national voice and 87% said we provide effective forums for collaboration. Nearly three quarters felt that they were listened to by the Alliance – that's why we will focus on improving dialogue across our membership, to ensure that members, no matter their interest or size, are able to influence our work to an even greater extent in the coming year.

We were pleased to join the Disability Confident scheme this year, as part of our wider commitment to inclusivity and diversity within the Alliance. As part of this, we reviewed our recruitment and interview practices.

In recruiting to the co-production group, we placed a heavy emphasis on ensuring a diversity of voices were represented. We were relatively successful in this, although further work

needs to be undertaken to ensure we are inclusive of minoritised communities throughout our work (for example, via the next iteration of My Neuro Survey).

We worked with a group of clinicians to conduct a focussed literature review examining available evidence on the relationship between protected characteristics and experience and outcomes of care, as well as prevalence and incidence of neurological conditions. The review was a first of its kind, and clearly highlighted the need to improve evidence to understand health inequalities in neurological conditions. In addition, we submitted a letter to the Lancet Neurology calling for improvements to evidence. Our particular thanks to our former trustee Dr Arani Nitkunan, Dr James Mitchell, Dr Kit Wu and Micha Vidot, for their commitment and time dedicated to this project.

We commissioned the National Council of Voluntary Organisations (NCVO) to conduct a light touch governance review. This was as part of a continuous improvement exercise to support The Neurological Alliance in assuring that its governance is in-line with sector good practice and identifying areas for improvement to further increase the impact of the Trustee Board in fulfilling the Alliance's mission.

### **3. Our structure, governance and management**

#### **3.1 Trustees selection**

We are governed by a Board of Trustees, made up of a minimum of three and a maximum of 14 people nominated by our members, recommended by our trustees and then elected by our members.

In advance of each Annual General Meeting (AGM), all members are invited to send in their nominations for the Board for available elected trustee posts. Details of the trustee candidates are then circulated to all members and votes are made by ballot at the AGM or sent in advance to the Chair using a proxy form; each member organisation is entitled to one vote, placed at the AGM.

After completing a three-year term, each trustee will stand down from the Board. Trustees who have completed only one term may stand for re-election; those who have served two consecutive terms must stand down for one year before they may stand again for the Board.

On joining the Alliance Board, all new trustees undertake a tailored induction programme. The trustees, who are also directors for the purpose of the Companies Act, who served during the year are listed in section 5.1.

#### **3.2 Structure**

We are a company limited by guarantee (no 02939840) and a registered charity (no 1039034). We are governed by Articles of Association and Byelaws. Our main activity is to secure the highest standards of care and treatment for every person affected by a neurological condition.

Our Board of Trustees is responsible for our governance and strategy and meets every quarter. Our Chief Executive is responsible for implementing the strategy and reports on its progress at the Board meetings. The Chief Executive reports directly to and is supervised by the Chair. They speak and meet regularly to discuss Alliance business.

Communication, both formal and informal, between Trustees and staff is frequent and effective.

### 3.2.1 Staff

Georgina Carr	Chief Executive and Company Secretary (from January 2020 – present)
Caroline Davies	Administration and Membership Officer (From October 2019 – present)
Miranda Lloyd	Communications and External Affairs Officer (March 2021 – present)
Jessica Mansel	Co-production Co-ordinator (February 2022 – July 2023)
Sam Mountney	Policy and External Affairs Manager (June 2021 – present)

### 3.2.2 Members

Full membership is open to national voluntary (non-statutory, non-profit) organisations who represent people affected by neurological conditions, including friends, families and carers organisations, who, in addition to the full benefits of membership, will have a right to vote at the AGM, have the right to nominate a trustee and an opportunity to influence our strategic direction. Subscriptions are income assessed.

Full affiliate membership is open to Regional Neurological Alliances operating on a non-statutory, non-profit basis. Affiliate members will pay a subscription rate which is not income assessed.

Associate status is open to professional associations and statutory authorities, who will play an active part in the Alliance but do not have the right to nominate a trustee or vote at the AGM. Subscriptions are income assessed. Regional Associations of Neurological Organisations can also be associates. They are staff led groups and will pay a subscription rate which is not income assessed.

Corporate supporter status is open to for-profit organisations, who cannot vote at the AGM or nominate a trustee.

Reciprocal partners are normally umbrella organisations whose aims and objectives match well with those of the Alliance. They cannot vote or influence our strategic direction.

### Members 2022 – 23

3 Million Steps <sup>1</sup>	<a href="https://3millionsteps.org">https://3millionsteps.org</a>
Alex TLC <sup>1</sup>	<a href="https://alextlc.org">https://alextlc.org</a>
Ataxia UK	<a href="http://www.ataxia.org.uk">www.ataxia.org.uk</a>
Autistica	<a href="http://www.autistica.org.uk">www.autistica.org.uk</a>
Batten Disease Family Association	<a href="http://www.bdfa-uk.org.uk">www.bdfa-uk.org.uk</a>
Behcets UK <sup>1</sup>	<a href="https://behcetsuk.org">https://behcetsuk.org</a>
The Brain and Spine Foundation	<a href="http://www.brainandspine.org.uk">www.brainandspine.org.uk</a>

The Brain Charity <sup>1</sup>	<a href="https://www.thebraincharity.org.uk">https://www.thebraincharity.org.uk</a>
Brain Research UK	<a href="http://www.brainresearchuk.org.uk">www.brainresearchuk.org.uk</a>
British Polio Fellowship	<a href="http://www.britishpolio.org.uk">www.britishpolio.org.uk</a>
Cavernoma Alliance UK	<a href="http://www.cavernoma.org.uk">www.cavernoma.org.uk</a>
Covid Aid <sup>1</sup>	<a href="http://www.covidaidcharity.org">www.covidaidcharity.org</a>
CMT United Kingdom	<a href="http://www.cmt.org.uk">www.cmt.org.uk</a>
CSF Leak <sup>1</sup>	<a href="https://csfleak.uk">https://csfleak.uk</a>
Cure Parkinson's Trust	<a href="http://www.cureparkinsons.org.uk">www.cureparkinsons.org.uk</a>
The Daisy Garland	<a href="http://www.thedaisygarland.org.uk">www.thedaisygarland.org.uk</a>
Different Strokes	<a href="http://www.differentstrokes.co.uk">www.differentstrokes.co.uk</a>
Downs Syndrome Research (DSRF)	<a href="http://www.dsrf-uk.org">www.dsrf-uk.org</a>
Dravet Syndrome UK	<a href="https://www.dravet.org.uk">https://www.dravet.org.uk</a>
Dystonia Society	<a href="http://www.dystonia.org.uk">www.dystonia.org.uk</a>
Epilepsy Action	<a href="http://www.epilepsy.org.uk">www.epilepsy.org.uk</a>
Epilepsy Research Institute UK	<a href="http://www.epilepsyresearch.org.uk">www.epilepsyresearch.org.uk</a>
FD UK	<a href="http://www.familialdysautonomia.co.uk">www.familialdysautonomia.co.uk</a>
FND Action	<a href="http://www.fndaction.org.uk">www.fndaction.org.uk</a>
FND Dimensions <sup>1</sup>	<a href="http://fnddimensions.org">http://fnddimensions.org</a>
FND Hope	<a href="http://www.fndhope.org">www.fndhope.org</a>
GAIN (Guillain-Barré and Associated Inflammatory Neuropathies)	<a href="http://www.gaincharity.org.uk">www.gaincharity.org.uk</a>
Hereditary Brain Aneurysms Support (HBA Support) <sup>1</sup>	<a href="https://www.hbasupport.org">https://www.hbasupport.org</a>
Huntington's Disease Association	<a href="http://www.hda.org.uk">www.hda.org.uk</a>
IIH UK	<a href="https://www.iih.org.uk">https://www.iih.org.uk</a>

Intractable Epilepsy <sup>1</sup>	<a href="https://www.intractable.org.uk">https://www.intractable.org.uk</a>
Matthew's Friends	<a href="https://www.matthewsfriends.org">https://www.matthewsfriends.org</a>
Migraine Trust	<a href="http://www.migrainetrust.org">www.migrainetrust.org</a>
Motor Neurone Disease Association	<a href="http://www.mndassociation.org">www.mndassociation.org</a>
Neuro Therapy Network (Was Multiple Sclerosis National Therapy Centres)	<a href="http://www.neurotherapynetwork.org.uk">www.neurotherapynetwork.org.uk</a>
Multiple Sclerosis Society	<a href="http://www.mssociety.org.uk">www.mssociety.org.uk</a>
Multiple Sclerosis Trust	<a href="http://www.mstrust.org.uk">www.mstrust.org.uk</a>
Multiple System Atrophy Trust	<a href="http://www.msatrust.org.uk">www.msatrust.org.uk</a>
Myaware	<a href="http://www.myaware.org">www.myaware.org</a>
Myelopathy.org	<a href="http://www.myelopathy.org">www.myelopathy.org</a>
Narcolepsy UK	<a href="http://www.narcolepsy.org.uk">www.narcolepsy.org.uk</a>
The National Hospital for Neurology And Neurosurgery Development Foundation	<a href="http://www.nationalbrainappeal.org">www.nationalbrainappeal.org</a>
National Tremor Foundation	<a href="http://www.tremor.org.uk">www.tremor.org.uk</a>
Nerve of My MS <sup>1</sup>	<a href="https://thenerveofmymms.org.uk">https://thenerveofmymms.org.uk</a>
Pans Pandas UK <sup>1</sup>	<a href="https://www.panspandasuk.org">https://www.panspandasuk.org</a>
Parkinson's UK	<a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a>
Pernicious Anaemia Society (PAS)	<a href="http://www.pernicious-anaemia-society.org">www.pernicious-anaemia-society.org</a>
Polio Survivors Network	<a href="http://www.poliosurvivorsnetwork.org.uk">www.poliosurvivorsnetwork.org.uk</a>
PSP Association	<a href="https://www.pspassociation.org.uk">https://www.pspassociation.org.uk</a>
Ring 20 Research and Support UK CIO	<a href="http://ring20researchsupport.co.uk">ring20researchsupport.co.uk</a>
Shift.MS <sup>1</sup>	<a href="https://shift.ms/">https://shift.ms/</a>
Spotlight YOPD	<a href="http://spotlightyopd.org">spotlightyopd.org</a>
SUDEP Action	<a href="http://www.sudep.org">www.sudep.org</a>

Sue Ryder	<a href="http://www.sueryder.org">www.sueryder.org</a>
Timothy Syndrome Alliance <sup>1</sup>	<a href="https://timothysyndrome.org">https://timothysyndrome.org</a>
Tourettes Action	<a href="http://www.tourettes-action.org.uk">www.tourettes-action.org.uk</a>
Tranverse Myelitis Society	<a href="http://www.myelitis.org.uk">www.myelitis.org.uk</a>
Trigeminal Neuralgia Association UK	<a href="http://www.tna.org.uk">www.tna.org.uk</a>
UK Acquired Brain Injury Forum	<a href="http://www.ukabif.org.uk">www.ukabif.org.uk</a>
<b>Associates</b>	
Association of British Neurologists	<a href="http://www.theabn.org">www.theabn.org</a>
Association of Chartered Physiotherapists in Neurology (ACPIN)	<a href="https://www.acpin.net">https://www.acpin.net</a>
British and Irish Association of Stroke Physicians (BIASP)	<a href="https://biasp.org">https://biasp.org</a>
British Paediatric Neurology Association (BPNA)	<a href="http://www.bpna.org.uk">www.bpna.org.uk</a>
Division of Neuropsychology (British Psychological Society)	<a href="http://www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology">www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology</a>
Independent Neurorehabilitation Providers Alliance (INPA)	<a href="https://in-pa.org.uk">https://in-pa.org.uk</a>
Neurology Academy	<a href="https://neurologyacademy.org">https://neurologyacademy.org</a>
<b>Corporate supporters</b>	
AbbVie	<a href="http://www.abbvie.co.uk">www.abbvie.co.uk</a>
Biogen	<a href="http://www.biogen.uk.com">www.biogen.uk.com</a>
Boston Scientific	<a href="https://www.bostonscientific.com">https://www.bostonscientific.com</a>
Sanofi Genzyme	<a href="http://www.genzyme.co.uk">www.genzyme.co.uk</a>
Lundbeck	<a href="https://www.lundbeck.com/uk">https://www.lundbeck.com/uk</a>
Merck Serono	<a href="http://www.merckserono.co.uk">www.merckserono.co.uk</a>

Novartis	<a href="http://www.novartis.co.uk">www.novartis.co.uk</a>
Pfizer <sup>1</sup>	<a href="https://www.pfizer.co.uk/science/pfizer-in-the-uk">https://www.pfizer.co.uk/science/pfizer-in-the-uk</a>
PTC Therapeutics <sup>1</sup>	<a href="https://www.ptcbio.com/">https://www.ptcbio.com/</a>
Roche	<a href="https://www.roche.com/">https://www.roche.com/</a>
Sandoz <sup>1</sup>	<a href="https://www.sandoz.com/">https://www.sandoz.com/</a>
Teva UK Limited	<a href="http://www.tevauk.com">www.tevauk.com</a>
UCB Pharma Ltd	<a href="http://www.ucb.co.uk">www.ucb.co.uk</a>
<b>Regional Neurological Alliances</b>	
Black Country Neurological Alliance <sup>3</sup>	<a href="http://www.blackcountryneuroalliance.org.uk">www.blackcountryneuroalliance.org.uk</a>
Bolton Neuro Voices	<a href="http://www.boltoncvs.org.uk">www.boltoncvs.org.uk</a>
Greater Manchester Neurological Alliance <sup>3</sup>	<a href="http://www.gmna.co.uk">www.gmna.co.uk</a>
Hampshire Neurological Alliance	<a href="https://www.hampshireneural.org.uk/index.html">https://www.hampshireneural.org.uk/index.html</a>
Lincolnshire Neurological Alliance <sup>3</sup>	<a href="http://www.lincolnshire-neurological-alliance.org.uk">www.lincolnshire-neurological-alliance.org.uk</a>
Merseyside and Cheshire Neurological Alliance	<a href="http://www.neurosupport.org.uk">www.neurosupport.org.uk</a>
Neuro Key (formerly Tees Valley, Durham, and North Yorkshire Neurological Alliance)	<a href="http://www.na-tvdny.org.uk">www.na-tvdny.org.uk</a>
West Berkshire Neurological Alliance	<a href="http://www.wbna.org.uk">www.wbna.org.uk</a>
<b>Reciprocal members</b>	
Genetic Alliance UK <sup>1</sup>	<a href="https://geneticalliance.org.uk">https://geneticalliance.org.uk</a>
National Voices	<a href="https://www.nationalvoices.org.uk">https://www.nationalvoices.org.uk</a>
Neurological Alliance of Ireland	<a href="http://www.nai.ie">www.nai.ie</a>
Neurological Alliance of Scotland	<a href="http://www.scottishneurological.org.uk">www.scottishneurological.org.uk</a>
Neurological Alliance of Wales	<a href="http://www.walesneurologicalalliance.org.uk">www.walesneurologicalalliance.org.uk</a>



<sup>1</sup>. New members in 2022-23

<sup>2</sup>. Ceased members in 2022-23

<sup>3</sup>. Organisation closed in 2022-23

### 3.2.3 The way we work

As a membership organisation, our whole ethos is to work in partnership. We work across the neurological community to identify common priorities for people affected by neurological conditions and then seek to influence, shape and support policy development to reduce inequalities, enhance their outcomes and, where possible, help them live for longer and in better health. Our activities are therefore based on a clear and shared sense of purpose. We work with the trustees, the Policy Group and Policy Steering group to determine our strategy and plans.

### 3.2.4 The Policy Group

Any member of the Alliance can take be part of the Policy Group. The group's purpose is to:

- Build collective ownership of the Alliance beyond staff and trustees and to promote team-working across the member organisations
- Provide a forum for policy, campaigns and public affairs staff of member organisations to share information and provide mutual support
- Feed into The Neurological Alliance policy development process
- More closely align member organisations' priorities with the collective needs of the Alliance; and
- Ensure that all member organisations, large and small, can contribute to the work of the Alliance.

### 3.2.5. Policy Group leads

Sam Carney	Health Policy and Improvement Lead, Parkinson's UK, Co-Chair (May 2022 – May 2023)
Charlotte Gerada	Policy and Public Affairs Manager, Huntington's Disease UK, Chair (June 2023 – present)
Dawn Golder	Executive Director, FND Hope UK, Co-Chair (Feb 2022 – May 2023)

### 3.3 Risk management

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to major risks. A risk management strategy, reviewed annually, is in place. We also have a risk-based reserves policy which mitigates one of our main financial risks in terms of having over three quarters of our income coming from just 13 funders (four charities, nine corporates).

### 4. Public benefit

Our work benefits people affected by a neurological condition and those who represent them. Sections 1 and 2 of this report set out our objectives, report on our activities and successes, and set out our plans for the current financial year.

The trustees consider that they have complied with their duty in s4 of the Charities Act 2011 to have due regard to the guidance on public benefit published by the Charity Commission. The trustees have considered this matter and concluded:

- That the aims of the organisation continue to be charitable
- That the aims and the work done give identifiable benefits to the charitable sector and both indirectly and directly to individuals in need
- That the benefits are for the public, are not unreasonably restricted in any way and certainly not by ability to pay
- That there is no detriment or harm arising from the aims or activities.

## **5. Reference and administrative details**

The Alliance is a registered charity (1039034) and company limited by guarantee (02939840) registered in England. The Alliance's registered office was, from 21<sup>st</sup> September 2019, The Junction, Station Road, Watford, WD17 1ET.

### **5.1 Trustees and the nominating organisation**

Alan Bowers	Sue Ryder (Treasurer) (stepped down July 2023)
Alison Fuller	Epilepsy Action (elected Nov 2022)
Amanda Swain	UK Acquired Brain Injury Forum (re-appointed Nov 2022)
Angie Pullen	Epilepsy Action (stepped down July 2022)
Cath Stanley	Huntington's Disease Association
Chris James	Motor Neurone Disease Association
David Martin	Multiple Sclerosis Trust (re-appointed Nov 2022, Chair)
Kripen Dhrona	British Polio Fellowship
Marc Smith	Brain and Spine Foundation (Vice-Chair)
Rob Music	Migraine Trust (elected Nov 2022)
Sarah Rawlings	MS Society
Victoria Wareham	Dystonia UK (elected Nov 2022)

During the year the Board, again, co-opted three independent trustees with the aim of achieving greater diversity on the Board in terms of the professional backgrounds of members. The co-opted trustees are:

David Garmon-Jones	Appointed February 2018, re-appointed February 2021
Ralph Gregory	Appointed February 2018, re-appointed February 2021
Arani Nitkunan	Appointed July 2020, stepped down May 2023

### **5.2 Professional advisors**

Bankers	CAF Bank Ltd, PO Box 289, West Malling, Kent, ME19 4TA Metro Bank PLC, One Southampton Row, London, WC1B 5HA
Accountants	Godfrey Wilson, 5th Floor, Mariner House, 62 Prince Street, Bristol, BS1 4QD
Independent Examiners	Goodman Jones LLP, 29-30 Fitzroy Square, London W1T 6LQ

## **6. Finances**

### **6.1 Investment**

Article 5.1.23 empowers the Alliance, with advice from a financial expert, to invest the funds of the Alliance as it sees fit, with consideration of the the suitability of investments and the need for diversification.

### **6.2 Subscriptions**

Subscription rates are determined by the organisational income of each member and associate. Subscriptions for affiliate members are at a fixed rate.

### **6.3 Reserves policy**

A reserves policy was agreed by trustees during 2022. This policy is a risk-based policy, to reflect the reality that any reduction in income or increasing in costs would take place over a period of time.

Having considered the risks, trustees consider it prudent that reserves should be maintained in order to cover the loss of income from one third of the significant income sources. This equates to approximately £55,000.

At the end of the year reserves of £95,920 (2022: £58,036) were held, of which £4,241 (21/22: £5,234) were restricted. This is £36,679 above the level of reserves the trustees calculate are required.

### **6.4 Financial position**

Income from membership subscriptions increased by 2% in the year to £95,952 (21/22: £94,229). In parallel, unrestricted corporate funding has increased from £110,296 to £149,225. We also received charitable donations totalling £1,142.

We also received generous support from UCB to develop a new epilepsy Service Improvement Navigator tool, totalling £9,015.

Our Policy and External Affairs Manager, Sam Mountney, was seconded to National Voices between October 2022 and February 2023. We received £21,981 for this secondment.

Overall, there is a surplus of £38,877 (before transfers) on the unrestricted funds (21/22 deficit of £60,267) and a deficit of £993 (before transfers) on restricted funds (21/22: deficit of £19,632). This leaves an overall surplus of £37,884 (21/22 deficit of £64,198) for the year.

### **6.5 Trustees' responsibilities statement**

The trustees (who are also directors of The Neurological Alliance for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charitable company's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the independent examiner is aware of that information.

### **6.6 Independent examiners**

At the AGM in November 2023, members agreed to delegate responsibility for selecting The Neurological Alliance's Independent Examiners for the forthcoming year and 2022-2023 accounts to the Board of Trustees.

The Board decided to appoint Goodman Jones LLP to be our independent examiner for 2023/24.

### **6.7 Small company provisions**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the Board of Trustees,

*Cath Stanley*

**Cath Stanley**

**Chair, Board of Trustees**

**Date:** 24-11-23

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**Independent Examiner's Report to the Trustees of The Neurological Alliance ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2023.

**Responsibilities and Basis of Report**

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of (enter body here), which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: *Martin Bailey*

Dated: 24-11-23

Martin Bailey

FCA

**Martin Bailey FCA**  
Goodman Jones LLP  
29/30 Fitzroy Square  
London  
W1T 6LQ

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)**  
**FOR THE YEAR ENDED 30 JUNE 2023**

	Note	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
<b>Income from:</b>					
Donations and legacies	4	1,166	-	1,166	5,768
Charitable activities	5	267,178	35,545	302,723	211,854
Investments	6	770	-	770	49
<b>Total income</b>		<b>269,114</b>	<b>35,545</b>	<b>304,659</b>	<b>217,671</b>
<b>Expenditure on:</b>					
Charitable activities	7	230,237	36,538	266,775	281,869
<b>Total expenditure</b>		<b>230,237</b>	<b>36,538</b>	<b>266,775</b>	<b>281,869</b>
<b>Net movement in funds</b>		<b>38,877</b>	<b>(993)</b>	<b>37,884</b>	<b>(64,198)</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		52,802	5,234	58,036	122,234
Net movement in funds		38,877	(993)	37,884	(64,198)
<b>Total funds carried forward</b>		<b>91,679</b>	<b>4,241</b>	<b>95,920</b>	<b>58,036</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**  
**REGISTERED NUMBER: 02939840**

---

**BALANCE SHEET**  
**AS AT 30 JUNE 2023**

---

	Note	2023 £	2022 £
<b>Fixed assets</b>			
Tangible assets	11	-	304
		<hr/>	<hr/>
		-	304
<b>Current assets</b>			
Debtors	12	27,040	13,605
Cash at bank and in hand		76,836	70,546
		<hr/>	<hr/>
		103,876	84,151
Creditors: amounts falling due within one year	13	(7,956)	(26,419)
		<hr/>	<hr/>
<b>Net current assets</b>		<b>95,920</b>	<b>57,732</b>
		<hr/>	<hr/>
<b>Total net assets</b>		<b>95,920</b>	<b>58,036</b>
		<hr/> <hr/>	<hr/> <hr/>
<b>Charity funds</b>			
Restricted funds	14	4,241	5,234
Unrestricted funds	14	91,679	52,802
		<hr/>	<hr/>
<b>Total funds</b>		<b>95,920</b>	<b>58,036</b>
		<hr/> <hr/>	<hr/> <hr/>

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

*Cath Stanley*  
.....  
**Cath Stanley**  
Chair of Trustees

Date: 24-11-23

---



---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**1. General information**

The Neurological Alliance is a registered charity and company limited by guarantee. Its charitable objects are set out in the Trustees' Report. Its registered office address is The Junction, Station Road, Watford, WD17 1EU.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared on the going concern basis under the historical cost convention, modified to include certain items at fair value. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in Sterling which is the functional currency of the Charity and monetary amounts are rounded to the nearest £.

The Neurological Alliance meets the definition of a public benefit entity under FRS 102.

**2.2 Company status**

The Charity is a company limited by guarantee. The members of the company are the Trustees named in the Trustee report section 5.1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

**2.3 Going concern**

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts and are of the opinion that the Charity will have sufficient resources to meet its liabilities as they fall due. The Trustees have made this assessment in respect of a period of one year from the date of approval of these accounts. The Trustees of the Charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the Charity to continue as a going concern.

**2.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**2. Accounting policies (continued)**

**2.5 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

Subscription income is invoiced in line with the financial year and recognised in the period to which it relates.

Corporate support represents amounts invoiced in the year.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**2.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Support costs are those costs incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the Charity and compliance with constitutional and statutory requirements.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**2. Accounting policies (continued)**

**2.7 Expenditure (continued)**

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. All expenditure is inclusive of irrecoverable VAT.

**2.8 Tangible fixed assets and depreciation**

Tangible fixed assets costing £NIL or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

Office equipment	- 3 years straight line
------------------	-------------------------

**2.9 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.10 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**2.11 Liabilities and Provision**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**2.12 Operating Leases**

Rentals under operating leases are charged to the Statement of Financial Activities incorporating Income and Expenditure Account on a straight-line basis over the lease term.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**2. Accounting policies (continued)**

**2.13 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**3. Critical accounting estimates and areas of judgement**

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Critical accounting estimates and assumptions:

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

In the opinion of the Trustees, there are no significant areas of estimation, uncertainty and critical judgements in applying accounting policies that have significant effect on the amounts recognised in the financial statements.

**4. Income from donations and legacies**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Donations	1,166	<b>1,166</b>	5,215
Legacies	-	-	553
	<hr/> 1,166 <hr/>	<hr/> <b>1,166</b> <hr/>	<hr/> 5,768 <hr/>
<i>Total 2022</i>	<hr/> <i>5,768</i> <hr/>	<hr/> <i>5,768</i> <hr/>	

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**5. Income from charitable activities**

	<b>Unrestricted funds 2023 £</b>	<b>Restricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Corporate support	171,226	-	<b>171,226</b>	110,296
Subscriptions	95,952	-	<b>95,952</b>	96,883
Projects	-	35,545	<b>35,545</b>	4,675
	<u>267,178</u>	<u>35,545</u>	<u><b>302,723</b></u>	<u>211,854</u>
<i>Total 2022</i>	<u>210,979</u>	<u>875</u>	<u>211,854</u>	

**6. Investment income**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Interest income	770	<b>770</b>	49
	<u>770</u>	<u><b>770</b></u>	<u>49</u>
<i>Total 2022</i>	<u>49</u>	<u>49</u>	

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**7. Analysis of expenditure on charitable activities**

**Summary by fund type**

	<b>Unrestricted funds 2023 £</b>	<b>Restricted funds 2023 £</b>	<b>Total 2023 £</b>	<b>Total 2022 £</b>
Policy Development	65,768	12,510	<b>78,278</b>	95,466
Members Activities	164,469	24,028	<b>188,497</b>	186,403
	<u>230,237</u>	<u>36,538</u>	<u><b>266,775</b></u>	<u>281,869</u>
<i>Total 2022</i>	<u>268,691</u>	<u>13,178</u>	<u>281,869</u>	

**8. Analysis of expenditure by activities**

	<b>Activities undertaken directly 2023 £</b>	<b>Support costs 2023 £</b>	<b>Total funds 2023 £</b>	<b>Total funds 2022 £</b>
Policy Development	52,845	25,433	<b>78,278</b>	95,466
Members Activities	185,566	2,931	<b>188,497</b>	186,403
	<u>238,411</u>	<u>28,364</u>	<u><b>266,775</b></u>	<u>281,869</u>
<i>Total 2022</i>	<u>257,581</u>	<u>24,288</u>	<u>281,869</u>	

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**9. Staff costs**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Wages and salaries	<b>156,847</b>	<i>130,233</i>
Social security costs	<b>10,725</b>	<i>8,848</i>
Contribution to defined contribution pension schemes	<b>8,847</b>	<i>7,706</i>
	<b>176,419</b>	<i>146,787</i>

The average number of persons employed by the Charity during the year was as follows:

	<b>2023</b>	<b>2022</b>
	<b>No.</b>	<b>No.</b>
Employees	<b>5</b>	<i>4</i>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	<b>2023</b>	<b>2022</b>
	<b>No.</b>	<b>No.</b>
In the band £60,001 - £70,000	<b>1</b>	<i>-</i>

Key management personnel remuneration, including employer's NIC and pension contributions, incurred by the Charity in the year totalled £77,193 (2022: £66,595).

**10. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 30 June 2023, expenses totalling £NIL were reimbursed or paid directly to Trustee (2022 - £172 to 2 Trustees).

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**11. Tangible fixed assets**

	Office equipment £
<b>Cost or valuation</b>	
At 1 July 2022	3,723
At 30 June 2023	<u>3,723</u>
<b>Depreciation</b>	
At 1 July 2022	3,419
Charge for the year	304
At 30 June 2023	<u>3,723</u>
<b>Net book value</b>	
At 30 June 2023	<u>-</u>
At 30 June 2022	<u>304</u>

**12. Debtors**

	2023 £	2022 £
<b>Due within one year</b>		
Other debtors	11,661	-
Prepayments and accrued income	15,379	13,605
	<u>27,040</u>	<u>13,605</u>

---



---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**13. Creditors: Amounts falling due within one year**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Trade creditors	<b>3,430</b>	<b>21,785</b>
Other creditors	<b>456</b>	<b>1,118</b>
Accruals and deferred income	<b>4,070</b>	<b>3,516</b>
	<b>7,956</b>	<b>26,419</b>

---

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**14. Statement of funds**

**Statement of funds - current year**

	<b>Balance at 1 July 2022 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Balance at 30 June 2023 £</b>
<b>Unrestricted funds</b>				
General Funds - all funds	<b>52,802</b>	<b>269,114</b>	<b>(230,237)</b>	<b>91,679</b>
<b>Restricted funds</b>				
NNAG Pathways	<b>5,234</b>	<b>-</b>	<b>(4,515)</b>	<b>719</b>
Epilepsy Tool	<b>-</b>	<b>9,015</b>	<b>(7,995)</b>	<b>1,020</b>
Neurolifenow	<b>-</b>	<b>12,500</b>	<b>(10,000)</b>	<b>2,500</b>
Outpatient Transformation	<b>-</b>	<b>14,030</b>	<b>(14,028)</b>	<b>2</b>
	<b>5,234</b>	<b>35,545</b>	<b>(36,538)</b>	<b>4,241</b>
<b>Total funds</b>	<b>58,036</b>	<b>304,659</b>	<b>(266,775)</b>	<b>95,920</b>

---

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

**14. Statement of funds (continued)**

**Statement of funds - prior year**

	<i>Balance at 1 July 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Transfers in/out £</i>	<i>Balance at 30 June 2022 £</i>
<b>Unrestricted funds</b>					
General Funds - all funds	113,069	216,796	(261,362)	(15,701)	52,802
<b>Restricted funds</b>					
NNAG Events	2,356	-	(2,631)	275	-
NNAG Pathways	6,809	-	(1,575)	-	5,234
Epilepsy Tool	-	875	(16,301)	15,426	-
	<u>9,165</u>	<u>875</u>	<u>(20,507)</u>	<u>15,701</u>	<u>5,234</u>
<b>Total funds</b>	<u><u>122,234</u></u>	<u><u>217,671</u></u>	<u><u>(281,869)</u></u>	<u><u>-</u></u>	<u><u>58,036</u></u>

NNAG events - events and activities to support the development of an epilepsy pathway.

NNAG support - programme management support for The National Neuro Advisory Group, includes organising meetings, workstreams and events.

Neurolifenow - funds received for a real-time survey which aims to provide routine patient experience data to support service improvement and positive public policy change.

Epilepsy Navigator Tool - a tool developed to provide a range of resources to support service development.

Outpatient Transformation - funds to provide improvements to outpatient services and resources.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**15. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	<b>Unrestricted funds 2023 £</b>	<b>Restricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Current assets	99,635	4,241	<b>103,876</b>
Creditors due within one year	(7,956)	-	<b>(7,956)</b>
<b>Total</b>	<b>91,679</b>	<b>4,241</b>	<b>95,920</b>

**Analysis of net assets between funds - prior year**

	<i>Unrestricted funds 2022 £</i>	<i>Restricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Tangible fixed assets	304	-	304
Current assets	78,917	5,234	84,151
Creditors due within one year	(26,419)	-	(26,419)
<b>Total</b>	<b>77,668</b>	<b>(19,632)</b>	<b>58,036</b>

**16. Pension commitments**

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £8,847 (2022 - £7,706).

Contributions totalling £456 (2022 - £1,118) were payable to the fund at the balance sheet date and are included in creditors.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**17. Operating lease commitments**

At 30 June 2023 the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	<b>2023</b>	<i>2022</i>
	<b>£</b>	<b>£</b>
Not later than 1 year	<b>9,000</b>	<i>9,000</i>

**18. Related party transactions**

Other than disclosed elsewhere in these financial statements, there were no related party transactions requiring disclosure during the current or previous year

---